Missing information, loopholes and weak oversight hamper efforts to uncover financial conflicts by researchers who test experimental drugs before companies seek government approval, an internal watchdog says.
As a result, the Food and Drug Administration’s screening system is unreliable, the Health and Human Services inspector general’s office says in a report being released today.